BioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1
Reuters2026/08/12 20:13- BioStem posts Q2 2026 net revenue of USD 7.9 million, up 29% sequentially.
- GAAP swings to a net loss of USD 9 million, or USD 0.52 a share.
- Gross profit totals USD 4.84 million, with gross margin flat at 61% versus Q1 2026.
- Operating expenses rise to USD 13.24 million, driven primarily by an expanding commercial team and infrastructure.
- Uplisted to Nasdaq Capital Market on Aug. 7; full-year 2026 revenue outlook lifted to USD 26 million-USD 29 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
